Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reuben Benjamin

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|November 19, 2024
Are we there yet? CAR-T therapy in multiple myelomaEitan Mirvis, Reuben Benjamin
Clinical Medicine (London, England)|August 4, 2018
Cancer immunotherapy with CAR-T cells - behold the futureCharlotte Graham, Rebecca Hewitson, Antonio Pagliuca, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 29, 2019
Monitoring Allogeneic CAR-T Cells Using Flow CytometryAgnieszka Jozwik, Alan Dunlop, Katy Sanchez, et al.
Cells|October 3, 2018
Allogeneic CAR-T Cells: More than Ease of Access?Charlotte Graham, Agnieszka Jozwik, Andrea Pepper, et al.
Plos One|June 26, 2015
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 InhibitionMaud Condomines, Jon Arnason, Reuben Benjamin, et al.
Micropublication Biology|August 22, 2025
Lymphoma-derived extracellular vesicles inhibit CAR T cell functionKhadiza Siddika, Katie R Flaherty, Reuben Benjamin, et al.
Clinical Kidney Journal|April 13, 2019
Risk of relapse of multiple myeloma following kidney transplantationSapna Shah, Maria Ibrahim, Michael Delaney, et al.
Cell Reports|July 12, 2025
CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patientsMolly S Cook, Ellen King, Katie R Flaherty, et al.
Journal of Thrombosis and Thrombolysis|June 7, 2019
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trialZara Sayar, Julia Czuprynska, Jignesh P Patel, et al.
Clinical and Experimental Immunology|May 27, 2026
Optimisation of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validationFahima Kausar, Christopher Davis, Daniel Larcombe-Young, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|November 19, 2024
Are we there yet? CAR-T therapy in multiple myelomaEitan Mirvis, Reuben Benjamin
Clinical Medicine (London, England)|August 4, 2018
Cancer immunotherapy with CAR-T cells - behold the futureCharlotte Graham, Rebecca Hewitson, Antonio Pagliuca, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 29, 2019
Monitoring Allogeneic CAR-T Cells Using Flow CytometryAgnieszka Jozwik, Alan Dunlop, Katy Sanchez, et al.
Cells|October 3, 2018
Allogeneic CAR-T Cells: More than Ease of Access?Charlotte Graham, Agnieszka Jozwik, Andrea Pepper, et al.
Plos One|June 26, 2015
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 InhibitionMaud Condomines, Jon Arnason, Reuben Benjamin, et al.
Micropublication Biology|August 22, 2025
Lymphoma-derived extracellular vesicles inhibit CAR T cell functionKhadiza Siddika, Katie R Flaherty, Reuben Benjamin, et al.
Clinical Kidney Journal|April 13, 2019
Risk of relapse of multiple myeloma following kidney transplantationSapna Shah, Maria Ibrahim, Michael Delaney, et al.
Cell Reports|July 12, 2025
CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patientsMolly S Cook, Ellen King, Katie R Flaherty, et al.
Journal of Thrombosis and Thrombolysis|June 7, 2019
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trialZara Sayar, Julia Czuprynska, Jignesh P Patel, et al.
Clinical and Experimental Immunology|May 27, 2026
Optimisation of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validationFahima Kausar, Christopher Davis, Daniel Larcombe-Young, et al.
Pageof 5